GGrantIndex
← Leaderboards

Shannon L. Meeks

Emory University

$9,405,167
Attributed
$16,296,106
Total exposure
8
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.2M · FY201025
$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$16,296,106 · 8

By mechanism

UG3$6,768,642 · 1
UH3$2,849,004 · 1
U54$2,574,000 · 2
R01$2,273,200 · 1
T32$958,350 · 1
K08$641,250 · 1

Top collaborators

Most similar at Emory University

Same institution · by research overlap

Others in their field

Top investigators on “Immune Response

Research focus

Immune ResponseFactor ViiiDesignF8 GeneResearch PersonnelHemophilia AAntibodiesExposure ToTrainingResourcesProgramsImmunogenicityInhibitor/AntagonistEpitopesEventMorbidity - Disease RateInfusion ProceduresLifeHemorrhageBiologicalB-LymphocytesSpecificityEnsureEnvironment

Grant awards (29)

A Severe Hemophilia A Intergenerational Cohort Research Program for the Study of Factor VIII Immunogenicity$2,849,004
UH3 · FY2025 · HL
Research Training in Pediatric Non-Malignant Hematology$375,327
T32 · FY2025 · HL · contact PI
A Severe Hemophilia A Intergenerational Cohort Research Program for the Study of Factor VIII Immunogenicity$2,465,319
UG3 · FY2024 · HL
Research Training in Pediatric Non-Malignant Hematology$212,166
T32 · FY2024 · HL · contact PI
A Severe Hemophilia A Intergenerational Cohort Research Program for the Study of Factor VIII Immunogenicity$2,511,468
UG3 · FY2023 · HL
Research Training in Pediatric Non-Malignant Hematology$370,857
T32 · FY2023 · HL · contact PI
A Severe Hemophilia A Intergenerational Cohort Research Program for the Study of Factor VIII Immunogenicity$1,791,855
UG3 · FY2022 · HL
Defining Initiating Factors Responsible for the Development of FVIII Inhibitors$454,640
R01 · FY2022 · HL · contact PI
Skills Development Core$280,800
U54 · FY2022 · HL · contact PI
Administrative Core$234,000
U54 · FY2022 · HL · contact PI
Defining Initiating Factors Responsible for the Development of FVIII Inhibitors$454,640
R01 · FY2021 · HL · contact PI
Skills Development Core$280,800
U54 · FY2021 · HL · contact PI
Administrative Core$234,000
U54 · FY2021 · HL · contact PI
Defining Initiating Factors Responsible for the Development of FVIII Inhibitors$454,640
R01 · FY2020 · HL · contact PI
Skills Development Core$280,800
U54 · FY2020 · HL · contact PI
Administrative Core$234,000
U54 · FY2020 · HL · contact PI
Defining Initiating Factors Responsible for the Development of FVIII Inhibitors$454,640
R01 · FY2019 · HL · contact PI
Skills Development Core$280,800
U54 · FY2019 · HL · contact PI
Administrative Core$234,000
U54 · FY2019 · HL · contact PI
Defining Initiating Factors Responsible for the Development of FVIII Inhibitors$454,640
R01 · FY2018 · HL · contact PI
Skills Development Core$280,800
U54 · FY2018 · HL · contact PI
Administrative Core$234,000
U54 · FY2018 · HL · contact PI
Mechanisms of Immunogenicity of Factor VIII$128,250
K08 · FY2014 · HL · contact PI
Fine epitope mapping of B cell response in patients with hemophilia A: Pilot$114,660
R21 · FY2014 · HL · contact PI
Mechanisms of Immunogenicity of Factor VIII$128,250
K08 · FY2013 · HL · contact PI
Fine epitope mapping of B cell response in patients with hemophilia A: Pilot$117,000
R21 · FY2013 · HL · contact PI
Mechanisms of Immunogenicity of Factor VIII$128,250
K08 · FY2012 · HL · contact PI
Mechanisms of Immunogenicity of Factor VIII$128,250
K08 · FY2011 · HL · contact PI
Mechanisms of Immunogenicity of Factor VIII$128,250
K08 · FY2010 · HL · contact PI